Early phase clinical trials of dual MEK‐PI3K inhibitor therapy for advanced solid cancers demonstrate low response rates but acceptable toxicity.6, 8 Response rates and disease control rates are low in unselected patients; approximately 5% and 19%, respectively.6, 8 No clear predictive factors have been identified, although response rates appear to be higher for RAS‐ or RAF‐mutated cancers than for those without these mutations. This evidence concerns the gene MAP2K7 and cancer.